394.00
+11.00
+(2.87%)
At close: January 17 at 5:15:01 PM GMT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
45,599.00
41,288.00
44,261.00
33,894.10
26,168.90
Cost of Revenue
6,392.00
4,742.00
5,098.00
3,647.40
2,767.00
Gross Profit
39,207.00
36,546.00
39,163.00
30,246.70
23,401.90
Operating Expense
85,599.00
84,845.00
66,524.00
48,435.30
34,458.60
Operating Income
-46,392.00
-48,299.00
-27,361.00
-18,188.60
-11,056.70
Net Non Operating Interest Income Expense
10,656.00
10,376.00
3,917.00
-893.60
-759.70
Other Income Expense
--
--
-127.00
--
--
Pretax Income
-35,736.00
-37,923.00
-23,571.00
-19,082.20
-11,816.40
Net Income Common Stockholders
-35,736.00
-37,923.00
-23,571.00
-19,082.20
-11,816.40
Diluted NI Available to Com Stockholders
-35,736.00
-37,923.00
-23,571.00
-19,082.20
-11,816.40
Basic EPS
-0.34
-0.37
-0.23
-0.21
-0.17
Diluted EPS
-0.34
-0.37
-0.23
-0.21
-0.17
Basic Average Shares
104,388.01
103,268.50
101,702.66
90,619.06
69,464.75
Diluted Average Shares
104,388.01
103,268.50
101,702.66
90,619.06
69,464.75
Total Operating Income as Reported
-46,392.00
-48,299.00
-27,361.00
-18,188.60
-11,056.70
Total Expenses
91,991.00
89,587.00
71,622.00
52,082.70
37,225.60
Net Income from Continuing & Discontinued Operation
-35,736.00
-37,923.00
-23,571.00
-19,082.20
-11,816.40
Normalized Income
-35,736.00
-37,923.00
-23,571.00
-19,082.20
-11,816.40
Interest Income
10,656.00
10,376.00
3,917.00
150.80
65.90
Interest Expense
116.00
--
126.90
1,044.40
825.60
Net Interest Income
10,656.00
10,376.00
3,917.00
-893.60
-759.70
EBIT
-46,392.00
-48,299.00
-27,361.00
-18,037.80
-10,990.80
EBITDA
-42,032.00
-44,128.00
-24,663.00
-16,613.90
-9,943.10
Reconciled Cost of Revenue
6,218.00
4,556.00
4,928.00
3,572.60
2,744.40
Reconciled Depreciation
4,360.00
4,171.00
2,698.00
1,423.90
1,047.70
Net Income from Continuing Operation Net Minority Interest
-35,736.00
-37,923.00
-23,571.00
-19,082.20
-11,816.40
Normalized EBITDA
-42,032.00
-44,128.00
-24,663.00
-16,613.90
-9,943.10
12/31/2020 - 3/29/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IOB.DU Ion Beam Applications SA
12.98
-2.41%
8C4.F CYBERDYNE Inc.
1.0440
-0.19%
CYBQF CYBERDYNE Inc.
1.0350
0.00%
2SE.F Sequana Medical NV
2.5400
-1.17%
NEOLA.ST Neola Medical AB (publ)
2.5400
-0.78%
ABT.VI Abbott Laboratories
110.40
+0.84%
2SE.SG Sequana Medical NV
2.5400
-2.68%
EPIS-B.ST Episurf Medical AB (publ)
0.1318
-2.23%
ABL.SG Abbott Laboratories
110.38
+0.44%
SBS.DE Stratec SE
32.10
+7.00%